Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

656
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
656
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

1.1K
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
1.1K
Drug Therapy01:28

Drug Therapy

385
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
385
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

2.4K
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
2.4K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and Moderators of Cognitive Behavioural Therapy for Psychosis Versus Other Psychological Interventions: An Individual-Participant Data Meta-Analysis.

Focus (American Psychiatric Publishing)·2026
Same author

Biological insights into schizophrenia from ancestrally diverse populations.

Nature·2026
Same author

Latent class analysis of symptoms across schizophrenia, schizoaffective disorder, and bipolar I disorder.

medRxiv : the preprint server for health sciences·2025
Same author

Relapse in Schizophrenia: A Systematic Review of Criteria for Clinical Studies and International Consensus Guidelines to Improve Them.

The American journal of psychiatry·2025
Same author

Response to the Letter to the Editor "Reflections on a study of electroconvulsive therapy for clozapine-refractory schizophrenia" (Jolly et al. Schizophrenia Research, 267 (2024) 32-33).

Schizophrenia research·2025
Same author

Corrigendum to "The danger of averages in the context of heterogeneity: Response to the letter to the editor of SCZ RES - role of ECT in patients with CRS - Markota et al., 2024" [Schizophr. Res. 269 (2024): 120-122].

Schizophrenia research·2024
Same journal

Digital Mental Health: Progress but not Perfection.

The Psychiatric clinics of North America·2026
Same journal

Advances in Mental Health Technology.

The Psychiatric clinics of North America·2026
Same journal

The Future of Digital Mental Health: A Literature Review.

The Psychiatric clinics of North America·2026
Same journal

Assessment and Treatment of Posttraumatic Stress Disorder via Digital Mental Health Technology.

The Psychiatric clinics of North America·2026
Same journal

Treatment of Obsessive-Compulsive Disorder via Mental Health Technology.

The Psychiatric clinics of North America·2026
Same journal

Digital Mental Health Treatments for Depression.

The Psychiatric clinics of North America·2026
See all related articles

Related Experiment Video

Updated: Mar 20, 2026

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.8K

Treatment-Resistant Schizophrenia.

Helio Elkis1, Peter F Buckley2

  • 1Instituto de Psiquiatria HC- FMUSP, Rua Ovidio Pires de Campos 785-São Paulo, SP-05403-010, Brazil.

The Psychiatric Clinics of North America
|May 25, 2016
PubMed
Summary
This summary is machine-generated.

Treatment-resistant schizophrenia (TRS) remains controversial despite clozapine treatment. New evidence highlights neurochemical mechanisms and reduced prefrontal cortex volume in TRS patients, updating previous findings.

Keywords:
ResistanceSchizophreniaTreatment

More Related Videos

Development of a Virtual Reality Assessment of Everyday Living Skills
10:32

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

19.4K
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

29.8K

Related Experiment Videos

Last Updated: Mar 20, 2026

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.8K
Development of a Virtual Reality Assessment of Everyday Living Skills
10:32

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

19.4K
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

29.8K

Area of Science:

  • Neuroscience
  • Psychiatry
  • Medical Research

Background:

  • Treatment-resistant schizophrenia (TRS) has been recognized for 50 years.
  • Clozapine is the gold standard treatment for TRS, yet controversies persist.
  • Understanding TRS mechanisms is crucial for improving patient outcomes.

Purpose of the Study:

  • To update and enhance previous reviews on treatment-resistant schizophrenia.
  • To incorporate new evidence from recent studies, clinical trials, systematic reviews, and meta-analyses.
  • To provide insights into the neurochemical and structural underpinnings of TRS.

Main Methods:

  • Review of recent scientific literature, including clinical trials and meta-analyses.
  • Analysis of neuroimaging studies focusing on structural brain differences.
  • Synthesis of evidence on neurochemical mechanisms implicated in TRS.

Main Results:

  • Progress has been made in elucidating the neurochemical mechanisms of TRS development.
  • Structural neuroimaging reveals a significant reduction in prefrontal cortex volume in TRS patients compared to non-TRS individuals.
  • New evidence from diverse sources enhances the understanding of TRS.

Conclusions:

  • Despite advancements, treatment-resistant schizophrenia remains an area of significant interest and debate.
  • Neuroimaging and neurochemical findings provide critical insights into TRS pathophysiology.
  • Continued research is essential for refining treatment strategies for TRS.